STATegics, Inc. is focused on the discovery and development of breakthrough new treatments for life-threatening rare neurodegenerative diseases. By targeting the tissue-protective cytokine receptor, STATegics has identified novel small molecules to address the underlying cause of Friedreich’s ataxia (FA), a rare neuromuscular disease for which no treatment is available.  In addition to addressing critical drivers in FA, STATegics’ molecules have the potential to treat multiple neuromuscular and neurodegenerative diseases. 


 STATegics, Inc., all rights reserved.
  Site Map